PET Imaging Study for Non-Hodgkin Lymphoma Patients Receiving CAR-T Therapy
This study is looking at a new imaging method using 64Cu-GRIP B and a PET scan in people with non-Hodgkin lymphoma (NHL) that has come back or not responded to previous treatments. You would be receiving CD19-directed CAR-T cell therapy, which is a type of immunotherapy. The researchers want to see if the 64Cu-GRIP B PET scan can detect granzyme B, a substance released by activated immune cells, in your tumors. This could help them understand if your tumors will respond well to CAR-T therapy. The study is open to adults aged 18 and older who have NHL and are planning to receive CD19-directed CAR-T therapy. Success for this study means seeing if the PET scan can identify tumors that are positive for granzyme B after CAR-T treatment. The current recruitment status is unclear.
- Study design
- This is an interventional study with a planned enrollment of 32 participants. It is the first time this imaging method is being used in lymphoma patients.
- What's involved
- You would receive an intravenous (IV) injection of 64Cu-GRIP B, undergo a PET imaging procedure, and potentially have an optional tumor biopsy.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 12 months after the end of the study intervention.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Randall Michael, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of positive tumors at the post-CAR-T scanFrom prior to CAR-T to Day 22 following CAR-T cell, approximately 32 days total
The proportion of known lesions with detectable radiotracer uptake on conventional imaging will be reported along with 95% binomial exact confidence intervals. Tumors will be defined as positive if they are focally avid with maximum standardized uptake value (SUVmax) \>1.5 fold above adjacent background.